Supernus Pharmaceuticals - SUPN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $36.00
  • Forecasted Upside: 9.09%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$33.00
▲ +1.11 (3.48%)

This chart shows the closing price for SUPN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Supernus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SUPN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SUPN

Analyst Price Target is $36.00
▲ +9.09% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Supernus Pharmaceuticals in the last 3 months. The average price target is $36.00, with a high forecast of $36.00 and a low forecast of $36.00. The average price target represents a 9.09% upside from the last price of $33.00.

This chart shows the closing price for SUPN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Supernus Pharmaceuticals. This rating has held steady since July 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/14/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/11/2024Piper SandlerDowngradeOverweight ➝ Neutral$41.00 ➝ $36.00
8/7/2024Piper SandlerDowngradeStrong-Buy ➝ Hold
2/28/2024Piper SandlerLower TargetOverweight ➝ Overweight$45.00 ➝ $41.00
11/9/2023Piper SandlerBoost TargetOverweight ➝ Overweight$42.00 ➝ $43.00
10/25/2023Piper SandlerLower TargetOverweight ➝ Overweight$43.00 ➝ $42.00
7/26/2023Piper SandlerLower Target$46.00 ➝ $43.00
5/10/2023Piper SandlerBoost Target$45.00 ➝ $46.00
1/23/2023Piper SandlerBoost TargetOverweight$40.00 ➝ $47.00
10/11/2022Piper SandlerLower Target$38.00 ➝ $36.00
9/6/2022Piper SandlerBoost Target$38.00
8/31/2022Piper SandlerBoost TargetOverweight$33.00 ➝ $38.00
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$40.00 ➝ $44.00
4/13/2021Jefferies Financial GroupUpgradeHold ➝ Buy$25.00 ➝ $40.00
2/3/2021Piper SandlerBoost TargetOverweight$30.00 ➝ $35.00
6/16/2020Piper SandlerUpgradeNeutral ➝ Overweight$25.00 ➝ $31.00
6/15/2020Jefferies Financial GroupInitiated CoverageHold$24.00
4/30/2020Piper SandlerBoost TargetCautious ➝ Neutral$17.00 ➝ $25.00
4/16/2020Stifel NicolausLower TargetHold$25.00 ➝ $24.00
11/8/2019Berenberg BankDowngradeBuy ➝ Hold
11/7/2019Stifel NicolausDowngradeBuy ➝ Hold$55.00 ➝ $23.00
11/6/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$46.00 ➝ $23.00
(Data available from 10/12/2019 forward)

News Sentiment Rating

1.11 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/16/2024
  • 6 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/15/2024
  • 4 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/15/2024
  • 10 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/14/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/14/2024
  • 7 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/13/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/12/2024
  • 13 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/12/2024

Current Sentiment

  • 13 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Supernus Pharmaceuticals logo
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $33.00
Low: $31.99
High: $33.12

50 Day Range

MA: $32.68
Low: $27.88
High: $35.16

52 Week Range

Now: $33.00
Low: $21.99
High: $35.44

Volume

395,924 shs

Average Volume

458,715 shs

Market Capitalization

$1.81 billion

P/E Ratio

366.67

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Supernus Pharmaceuticals?

The following Wall Street research analysts have issued reports on Supernus Pharmaceuticals in the last year: Piper Sandler, and StockNews.com.
View the latest analyst ratings for SUPN.

What is the current price target for Supernus Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Supernus Pharmaceuticals in the last year. Their average twelve-month price target is $36.00, suggesting a possible upside of 9.1%. Piper Sandler has the highest price target set, predicting SUPN will reach $36.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $36.00 for Supernus Pharmaceuticals in the next year.
View the latest price targets for SUPN.

What is the current consensus analyst rating for Supernus Pharmaceuticals?

Supernus Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SUPN, but not buy more shares or sell existing shares.
View the latest ratings for SUPN.

What other companies compete with Supernus Pharmaceuticals?

How do I contact Supernus Pharmaceuticals' investor relations team?

Supernus Pharmaceuticals' physical mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company's listed phone number is (301) 838-2500 and its investor relations email address is [email protected]. The official website for Supernus Pharmaceuticals is www.supernus.com. Learn More about contacing Supernus Pharmaceuticals investor relations.